ALAMEDA, Calif. -- (BUSINESS WIRE) -- InSite Vision Incorporated (OTCBB: INSV) announced today that it will report financial results for the third quarter ended September 30, 2013 on Tuesday, November 12, 2013.
InSite Vision management will host a conference call that day beginning at 4:30 p.m. ET/1:30 p.m. PT to discuss third quarter 2013 financial results and to review recent accomplishments and upcoming milestones. Investors will be invited to ask questions following management’s prepared remarks.
Analysts and investors can participate in the conference call by dialing 888-679-8018 for domestic callers and 617-213-4845 for international callers using the pass code 40686089. Interested parties are encouraged to pre-register to avoid delays at https://www.theconferencingservice.com/prereg/key.process?key=P3EKYKJPK. The live conference call will also be webcast and available on the Investor Relations page of the company's website at www.insitevision.com. Please log onto the webcast at least 10 minutes prior to the start of the call to ensure time for any software downloads that may be required. A telephone replay will be available following the conclusion of the call by dialing 888-286-8010 for domestic callers and 617-801-6888 for international callers using the pass code 91465498.
A press release detailing third quarter 2013 financial results will be posted to the company's website and furnished to the Securities and Exchange Commission on a Form 8-K.
About InSite Vision
InSite Vision is advancing new ophthalmologic products for unmet eye care needs based on its innovative DuraSite® platform technologies. The DuraSite and DuraSite 2 drug delivery systems extend the duration of drug retention on the surface of the eye, thereby reducing the frequency of treatment and improving the efficacy of topical drugs.
The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, sold in the U.S. by Merck, and Besivance® (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch + Lomb. InSite Vision is also advancing three novel ophthalmic therapeutics through Phase 3 clinical studies: AzaSite Plus™ and DexaSite™ for the treatment of eye inflammation, and BromSite™ for pain and inflammation associated with ocular surgery. For further information on InSite Vision, please visit www.insitevision.com, or connect with the Company on Facebook, Twitter, LinkedIn, Google+, and SlideShare.
AzaSite® and DuraSite® are registered trademarks
of InSite Vision Incorporated.
AzaSite Plus™, BromSite™ and DexaSite™ are trademarks of InSite Vision Incorporated.
BESIVANCE® is a registered trademark of Bausch + Lomb Incorporated.